While sarcoidosis can lead to hospital admission, in-hospital deaths among people with sarcoidosis are most often caused by other conditions rather than the disease itself, according to a real-world national study in Spain. Common causes of death included infections, cardiovascular disease, cancer, and blood clots known as venous thromboembolism…
News
People with pulmonary sarcoidosis who are older at diagnosis or have more severe lung damage may face a higher risk of death. That’s according to a large study from Spain, in which researchers found that being older than 50 and having a Composite Physiological Index (CPI) score above 35…
People with autoimmune diseases — especially Sjögren’s disease, which affects the glands that produce tears and saliva — may have a significantly higher risk of developing sarcoidosis, according to a study in Japan. The strongest association was seen with Sjögren’s disease, while other autoimmune conditions were also significantly linked…
Atyr Pharma will meet with the U.S. Food and Drug Administration (FDA) next month to review results from the Phase 3 EFZO-FIT clinical trial and discuss the path forward for efzofitimod as a treatment for pulmonary sarcoidosis. The meeting follows a company announcement last year that the trial…
A bipartisan group of U.S. lawmakers is joining forces to form a new team — the Congressional Sarcoidosis Caucus — to help lead a nationwide fight against sarcoidosis, a rare disease that can affect any of the body’s organs. The newly formed caucus will work to raise awareness about…
The Sarcoidosis Research Institute (SRI) will host a free virtual conference in April aimed at empowering people affected by sarcoidosis. The conference, called Empowering the Patient Journey: Living Well with Sarcoidosis, will take place from 1 to 5 p.m. EST April 25. It will feature expert-led presentations and…
The global burden of pulmonary sarcoidosis and other interstitial lung diseases (ILDs) increased significantly between 1990 and 2023, with rises in new and total cases, deaths, and loss of healthy years, a study showed. The data also showed that the burden varies by region and is highest among adults…
Receiving a high dose of Priovant Therapeutics’ oral treatment candidate brepocitinib in a clinical trial led to substantial reductions in symptom severity for all participants with cutaneous sarcoidosis, in which the disease affects the skin, new data show. Further, no serious side effects were reported in the…
A new artificial intelligence (AI) model predicted sudden cardiac death (SCD) risk more accurately than current clinical guidelines in people with cardiac sarcoidosis, according to a U.S. study. The AI model, called Multimodal Artificial Intelligence for Ventricular Arrhythmia Risk Stratification in Cardiac Sarcoidosis (MAARS-CS), estimates risk using heart MRI…
The Foundation for Sarcoidosis Research (FSR) has announced $400,000 in new funding to support early-stage research projects aimed at improving the diagnosis, treatment, and management of the rare inflammatory disease. The funding is divided into four grants of $100,000 each. Two were awarded to projects focused on cardiac…
Recent Posts
- Most deaths in hospitalized sarcoidosis patients linked to other causes
- A night of nostalgia proves compassion counts with chronic illness
- 2 factors linked to higher risk of death for lung sarcoidosis patients in study
- Autoimmune diseases tied to higher sarcoidosis risk, new study finds
- Atyr to discuss efzofitimod’s future with FDA after Phase 3 sarcoidosis trial
- How do you celebrate Autoimmune Awareness Month?
- New congressional caucus to advocate for sarcoidosis research, funding
- Free virtual conference aims to empower sarcoidosis community
- The best advice I ever got for dealing with a rare disease
- Sarcoidosis and ILD burden rising globally, new analysis finds